Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5488447 | 0.85 | CNR1 (0.41) | CNR1HTTGPR35GPR55MEN1 | |
| SCHEMBL5482098 | 0.82 | HTT (0.39) | CNR1HTTGPR35GPR55LMNA | |
| SCHEMBL5475383 | 0.81 | MAPT (0.52) | CNR1HTTGPR35GPR55LMNA | |
| SCHEMBL5482300 | 0.81 | SMN1; SMN2 (0.52) | CNR1HTTGPR35GPR55MEN1 | |
| SCHEMBL5478213 | 0.70 | CNR1 (0.40) | CNR1HTTGPR35GPR55CYP19A1 | |
| SCHEMBL5485042 | 0.63 | GPR55 (0.68) | CNR1HTTGPR35GPR55MEN1 | |
| SCHEMBL5486611 | 0.63 | CNR1 (0.63) | CNR1HTTGPR35GPR55MEN1 | |
| SCHEMBL4423477 | 0.63 | ATM (0.48) | MAPTKMT2ANPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL9342160 | 0.61 | LMNA (0.73) | CYP19A1MEN1LMNAMAPTKMT2A | |
| SCHEMBL5483658 | 0.61 | CNR1 (0.65) | CNR1HTTGPR35GPR55MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | TOPO TARGET A/S (DK) | 2007-12-27 | — | — | US | claimed |
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | TOPO TARGET A/S (DK) | 2007-12-27 | — | — | US | disclosed |
| EP-1734951-A2 | DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TopoTarget A/S (DK) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097107-A2 | DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TOPOTARGET A/S (DK) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | MTOR, RICTOR, CDK4 | CNR1 973/4885HTT 1880/4885GPR35 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.